Laurion Capital Management LP Inozyme Pharma, Inc. Transaction History

Laurion Capital Management LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	SELL	$4.33 - $7.31 $1.19 Million - $2.02 Million	-275,656 Reduced 68.54%	126,541 $564,000
Q1 2024 May 15, 2024	SELL	$4.14 - $7.66 $642,246 - $1.19 Million	-155,132 Reduced 27.83%	402,197 $3.08 Million
Q4 2023 Feb 14, 2024	BUY	$2.71 - $4.5 $831,864 - $1.38 Million	306,961 Added 122.6%	557,329 $2.37 Million
Q2 2023 Aug 14, 2023	SELL	$4.93 - $6.74 $105,659 - $144,451	-21,432 Reduced 7.89%	250,368 $1.39 Million
Q2 2022 Aug 15, 2022	BUY	$3.2 - $5.96 $837,760 - $1.56 Million	261,800 Added 2618.0%	271,800 $1.3 Million
Q1 2022 May 16, 2022	SELL	$3.87 - $7.55 $13,119 - $25,594	-3,390 Reduced 25.32%	10,000 $41,000
Q4 2021 Feb 14, 2022	SELL	$5.58 - $11.5 $319,789 - $659,065	-57,310 Reduced 81.06%	13,390 $91,000
Q3 2021 Nov 15, 2021	BUY	$11.12 - $19.4 $786,184 - $1.37 Million	70,700 New	70,700 $819,000
Q2 2021 Aug 13, 2021	SELL	$15.19 - $21.2 $155,697 - $217,300	-10,250 Closed	0 $0
Q3 2020 Nov 13, 2020	BUY	$17.54 - $30.2 $179,785 - $309,550	10,250 New	10,250 $269,000

53M

3.7K

5.8K

Ticker INZY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 40,145,700
Market Cap $118M
Description
Inozyme Pharma, Inc., a rare disease biopharmaceutical company, engages in developing therapeutics for treating abnormal mineralization impacting the vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant protein to treat the rare genetic diseases of ENPP1 and ABCC6 deficiencies, ...

Get notified when there are updates to the investment portfolio of Laurion Capital Management LP, based on Form 13F filings with the SEC.

Stay updated on Laurion Capital Management LP with notifications on news.